Arjan S. Dhoot

Arjan S. Dhoot

Auto-generated profile, based on publicly available information

Arjan S. Dhoot

Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Survey of Ophthalmology
Verified
Journal Article
Closed access
ADArjan S. Dhoot
Arjan S. Dhoot
MPMarko M. Popovic
Marko M. Popovic
PNPrem A.H. Nichani
Prem A.H. Nichani
AEArshia Eshtiaghi
Arshia Eshtiaghi
AMAndrew Mihalache
Andrew Mihalache
RMRajeev H. Muni
Rajeev H. Muni

4 February 2022 in Neonatology
Verified
Journal Article
Open access
PDF file
CYCaberry W. Yu
Caberry W. Yu
MPMarko M. Popovic
Marko M. Popovic
ADArjan S. Dhoot
Arjan S. Dhoot
PAParnian Arjmand
Parnian Arjmand
RMRajeev H. Muni
Rajeev H. Muni
PKPeter J. Kertes
Peter J. Kertes
Introduction: Current national guidelines use gestational age (GA) and birth weight (BW) as their basis for retinopathy of prematurity (ROP) screening. The strength of association of these and other demographic risk factors is inconsistent across studies. This review aims to evaluate the strength of association of documented risk factors for ROP in large sample, population-based studies. Methods: MEDLINE, EMBASE, and Cochrane Library were searched from January 2010 to May 2020. Original studies reporting the risk of ROP in a region and demographic risk factors were included. Results: Eighteen studies comprising 342,005 infants were included. The overall risk of ROP in preterm infants was 18.8%. For every week decrease in GA, there was a median adjusted odds ratio (aOR) of 1.4 times (range 1.2–1.9) of developing ROP. For every 100-g decrease in BW, the median aOR was 1.8 times (range 1.2–2.7). Higher risk was found in infants with neonatal sepsis and bronchopulmonary dysplasia. The risk of any, severe, and treatment-requiring ROP was highest for 23 weeks GA, which was 66.5, 40.3, and 39.4%, respectively. Regions with higher neonatal mortality rates had the highest mean GA of infants with ROP. Conclusion: For every week decrease in GA and every 100-g decrease in BW, there was a median of 1.4 times and 1.8 times the odds of developing ROP, respectively. Further research is required to clarify the role of additional risk factors.

1 March 2023 in Eye
Verified
Journal Article
Open access
PDF file
PNPrem A. H. Nichani
Prem A. H. Nichani
MPMarko M. Popovic
Marko M. Popovic
ADArjan S. Dhoot
Arjan S. Dhoot
APAnanya Pathak
Ananya Pathak
RMRajeev H. Muni
Rajeev H. Muni
PKPeter J. Kertes
Peter J. Kertes
Intravitreal injections of antiangiogenic agents are pivotal in treating neovascular age-related macular degeneration (nAMD). The comparative efficacy and safety of treat-and-extend (T&E) versus bimonthly, monthly, and pro re nata (PRN) dosing remains unclear. A systematic review and meta-analysis of English-language RCTs reporting on efficacy and/or safety outcomes of dosing regimens of anti-VEGF agents in nAMD was performed. Best-corrected visual acuity (BCVA, ETDRS letters) at last follow-up represented the primary endpoint, while central subfield thickness (CSFT, μm), injection burden, and ocular adverse events were secondary endpoints. A random effects meta-analysis was performed, and 95% confidence intervals were calculated. Across six RCTs, 781 T&E-, 663 monthly-, 130 PRN-, and 123 bimonthly treated eyes were included. Mean changes in BCVA and CSFT at last follow-up were similar between T&E versus monthly (WMD, –0.62 letters; 95% CI, –2.12 to 0.87; P = 0.41; WMD, 5.30 microns; 95% CI, –10.67 to 21.26; P = 0.52, respectively), bimonthly (WMD, 1.68 letters; 95% CI, –3.55 to 6.91; P = 0.53; WMD, –18.91 microns; 95% CI, –46.41 to 8.60; P = 0.18, respectively), and PRN (BCVA WMD, 1.08 letters; 95% CI, –2.95 to 5.11; P = 0.60) regimens. T&E was associated with a reduced injection burden versus monthly (WMD, –4.52 injections; 95% CI, –6.66 to 2.39; P < 0.001) but higher injection burden versus PRN (WMD, 1.81 injections; 95% CI, 1.12 to 2.51; P < 0.001) dosing. There was no significant difference in safety outcomes amongst comparators. There was no significant difference in efficacy and safety between T&E, bimonthly, monthly, and PRN dosing. T&E resulted in fewer injections versus monthly and fewer clinic visits versus PRN.

9 May 2022 in Ophthalmologica
Verified
Journal Article
Open access
PDF file
PNPrem A. H. Nichani
Prem A. H. Nichani
ADArjan S. Dhoot
Arjan S. Dhoot
MPMarko M. Popovic
Marko M. Popovic
AEArshia Eshtiaghi
Arshia Eshtiaghi
AMAndrew Mihalache
Andrew Mihalache
RMRajeev H. Muni
Rajeev H. Muni
Purpose: The efficacy and safety of scleral buckling (SB) versus combination SB and pars plana vitrectomy (SB + PPV) for rhegmatogenous retinal detachment (RRD) repair remains unclear. Methods: A systematic review and meta-analysis was conducted to identify comparative studies published from Jan 2000–Jun 2021 that reported on the efficacy and/or safety following SB and SB + PPV for RRD repair. Final best-corrected visual acuity (BCVA) represented the primary endpoint, while reattachment rates and ocular adverse events were secondary endpoints. A random-effects meta-analysis was performed, and 95% confidence intervals were calculated. Results: Across 18 studies, 3912 SB and 3300 SB + PPV eyes were included. Final BCVA was nonsignificantly different between SB and SB + PPV (20/38 vs. 20/66 Snellen; WMD = −0.11 LogMAR; 95% CI: [–0.29, 0.07]; p = 0.23). Primary reattachment rate was similar between procedures (p = 0.74); however, SB alone achieved a significantly higher final reattachment rate (97.40% vs. 93.86%; RR = 1.03; 95% CI: [1.00, 1.06]; p = 0.04). Compared to SB + PPV, SB alone had a significantly lower risk of postoperative macular edema (RR = 0.69; 95% CI: [0.47, 1.00]; p = 0.05) and cataract formation (RR = 0.34; 95% CI: [0.12, 0.96]; p = 0.04). The incidence of macular hole, epiretinal membrane, residual subretinal fluid, proliferative vitreoretinopathy, elevated intraocular pressure, and extraocular muscle dysfunction were similar between SB and SB + PPV. Conclusions: There was no significant difference in final BCVA between SB + PPV and SB alone in RRD. SB alone offers a slightly higher final reattachment rate along with a reduced risk of macular edema and cataract. Primary reattachment rate and the incidence of other complications were similar between the two procedures.

23 May 2021 in Ophthalmic Epidemiology
Verified
Journal Article
Closed access
ADArjan S. Dhoot
Arjan S. Dhoot
MPMarko M. Popovic
Marko M. Popovic
YLYerin Lee
Yerin Lee
SLSiwoo Lee
Siwoo Lee
JMJonathan A. Micieli
Jonathan A. Micieli
Purpose: There are currently no available aids for authors when selecting ophthalmology journals to submit their manuscripts. We aim to provide comprehensive data on the duration from submission to various stages of the publication process and assess factors influencing time to publication in ophthalmology journals. Methods: A list of ophthalmology journals was obtained from the 2019 Web of Science Journal Citation Report. Journal characteristics, such as five-year impact factor, number of authors per article, journal type, and number of multi-institutional articles, were collected. The dates of submission, acceptance, electronic and print publication for all articles published in an ophthalmology journal in 2019 were determined. Results: In total, 56 journals and 8835 research articles were included. Of these articles, 3591 (40.6%) were open access and 4837 (54.7%) were multi-institutional. In 2019, most publications came from the United States of America (n = 1973), China (n = 1069) and Germany (n = 602). Significant associations were found between various predictors and a reduced mean number of days from submission to electronic publication: increased journal five-year impact factor (p = .026), more authors (p = .028), publishing in a hybrid journal (both open-access and subscription articles) versus an open-access journal (p = .021), and a reduced proportion of multi-institutional articles in a journal (p = .030). Conclusions: There is a wide variation in the time to acceptance and publication in ophthalmology journals. Authors can expect a shorter time to publication when publishing in high-impact journals.

1 June 2023 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
ADArjan S. Dhoot
Arjan S. Dhoot
MPMarko M. Popovic
Marko M. Popovic
SLSoomin Lee
Soomin Lee
SESherif El-Defrawy
Sherif El-Defrawy
MSMatthew B. Schlenker
Matthew B. Schlenker